SUNNYVALE, Calif., May 16, 2012 - Accuray Incorporated
(Nasdaq: ARAY), the premier radiation oncology company,
announced today that for the first time in Europe, at ESTRO
31, the Annual Congress of the European Society for
Therapeutic Radiology and Oncology in Barcelona, Spain, the
company showcased side-by-side the CyberKnife®
Robotic Radiosurgery System and the TomoTherapy®
System with a record 3,000 booth attendees.
Additionally, during ESTRO Accuray announced and
displayed the availability of the VoLO Planning Solution for
the TomoTherapy System, a combination of a new dose
calculation algorithm (NVBB - Non-Voxel Broad Beam) and a
specifically designed computing hardware based on Graphics
Processor Unit (GPU) technology. The VoLO Planning Solution
provides intuitive, interactive plan generation, reducing
significantly treatment planning time while further enhancing
treatment quality.

On Friday, May 11 Accuray hosted a symposium chaired by Prof,
Eric Lartigau, M.D., Ph.D., Oscar Lambret Cancer Center,
Lille, France. Euan S. Thomson, Ph.D., president and CEO of
Accuray presented the "Vision of Accuray" and discussed
Accuray's continued commitment to clinical and technical
research and development. Clinical data was presented by Dr.
Noelle van der Voort van Zyp, Erasmus MC - Daniel den Hoed
Cancer Centre in Rotterdam, Netherlands that demonstrated the
benefits of CyberKnife SBRT (Stereotactic Body Radiation
Therapy) in the treatment of peripheral and centrally located
non-small cell lung cancer, including excellent local tumor
control and low toxicity. Prof. Vincent Gregoire, M.D.,
Ph.D., FRCR, UCL-Saint Luc University Hospital, Brussels,
Belgium, a TomoTherapy site, discussed the potential need for
adaptive treatment of head and neck cancer, illustrating how
daily image guidance could identify modification in
dose delivery compared to the planned dose distribution, and
could trigger plan adaptation based on changing
characteristics of tumor and organs at risk. Finally, Dr.
Nicholas van As, Royal Marsden, London, United Kingdom gave
an overview of the newly launched
PACE study, a multicenter randomized comparative clinical
study of CyberKnife prostate SBRT, surgery and conventionally
fractionated radiotherapy. With more than 300 people in
attendance, the symposium proved to be a successful meeting
and a chance for leaders in the field to share and present
important clinical outcomes.

"The combination of quality presentations on treatment
outcomes from both the CyberKnife and TomoTherapy Systems and
the consistent interest in Accuray's new product offerings
reinforces our place as an innovative leader in the radiation
oncology industry," said Euan S. Thomson, Ph.D., president
and chief executive officer of Accuray. "Accuray has
solidified its presence in advancing the standards for SBRT
and IG-IMRT treatment and continues to make strides toward
helping patients live longer, better lives."

Continuing the expansion of clinical evidence for both the
CyberKnife and TomoTherapy Systems, more than 110
presentations on experience with both technologies were
presented as part of ESTRO's scientific program. In
particular, Dr. Mischa Hoogeman, Erasmus MC-Daniel den Hoed
Cancer Center, Rotterdam, The Netherlands presented seven
years of clinical experience in real-time lung tumor tracking
using the CyberKnife System's unique motion management
capabilities including the Synchrony® Respiratory Tracking
System, which enables real-time tracking and correction for
tumors that move with respiration. Dr. Hoogeman also reported
outstanding technical and clinical accuracy during treatment
with the CyberKnife System thus allowing for reduced margins
and the ability to account for uncertainty in target
position. To date Erasmus has treated more than 700 tumors in
the lung with the CyberKnife System. Additionally,
several abstracts focused on the systematic use of the
TomoTherapy System's daily megavoltage computed tomography
(MVCT) to ensure accurate patient set-up and to permit
accurate calculation of delivered dose and sophisticated
treatment plan adaptation. Dr. Nadia Di Muzio, Istituto
Scientifico H.S. Raffaele, Milano, Italy presented the
general rationale for adaptive radiotherapy including the
group's work on adapting margins during IMRT for pre-op
rectal cancer treatment.

Both the TomoTherapy and CyberKnife Systems allow for the
treatment of a broad range of applications throughout the
body, as demonstrated by reports of excellent clinical
outcomes for a variety of indications. These outcomes prove
that both technologies allow clinicians the opportunity to
offer patients accurate and high quality individualized
treatments that best suit their individual needs.

About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale,
Calif., is the premier radiation oncology company that
develops, manufactures and sells personalized innovative
treatment solutions that set the standard of care, with the aim
of helping patients live longer, better lives. The Company's
leading edge technologies - the CyberKnife and TomoTherapy
Systems - are designed to deliver radiosurgery, stereotactic
body radiation therapy, intensity modulated radiation therapy,
image guided radiation therapy, and adaptive radiation therapy.
To date, 635 systems have been installed in leading hospitals
around the world. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements
of historical fact are forward-looking statements and are
subject to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release relate, but are not limited,
to the anticipated benefits of the VoLO technology, the
Company's ability to continue to enhance the performance of
its products, clinical efficiency and effectiveness the
products, and the Company's leadership position in radiation
oncology innovation. Forward-looking statements are subject
to risks and uncertainties that could cause actual results to
differ materially from expectations, including risks detailed
from time to time under the heading "Risk Factors"
in the Company's reports Form 10-Q for the first, second and
third quarters of fiscal 2012. Forward-looking statements
speak only as of the date the statements are made and are
based on information available to the Company at the time
those statements are made and/or management's good faith
belief as of that time with respect to future events. The
Company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes
in assumptions or changes in other factors affecting
forward-looking information, except to the extent required by
applicable securities laws. Accordingly, investors should not
place undue reliance on any forward-looking statements.